Andrea Hetzenecker1, Tatjana Roth1, Christoph Birner1, Lars S Maier1, Michael Pfeifer1,2,3, Michael Arzt4. 1. Department of Internal Medicine II, Cardiology and Pneumology, Centre for Sleep Medicine, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, 93053, Regensburg, Germany. 2. Department of Pneumology, Donaustauf Hospital, Donaustauf, Germany. 3. Clinic for Pulmonology, Hospital of the Order of St. John of God Regensburg, Regensburg, Germany. 4. Department of Internal Medicine II, Cardiology and Pneumology, Centre for Sleep Medicine, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, 93053, Regensburg, Germany. michael.arzt@ukr.de.
Abstract
OBJECTIVES: Poor sleep quality is common in patients with chronic heart failure (CHF). This study tested the hypothesis that adaptive servo-ventilation (ASV) therapy in CHF patients whose central sleep apnoea (CSA) was not suppressed by continuous positive airway pressure (CPAP) (CPAP-non-responders) would improve sleep quality compared to CPAP-responders receiving ongoing CPAP therapy. METHODS: Eighty-two patients with CHF (65 ± 9 years, left ventricular ejection fraction 35 ± 16 %) and CSA [apnoea-hypopnoea index (AHI) ≥15/h] were retrospectively studied. Within an average of 47 days, patients were reevaluated on CPAP therapy and stratified according to their suppression of CSA: 34 were CPAP-non-responders switched to ASV therapy the following day and 48 were CPAP-responders who continued on CPAP therapy. Polysomnographic parameters were assessed in the diagnostic night and on the last night of PAP therapy (CPAP or ASV) before the patient was discharged with the final pressure settings. RESULTS: Compared with the CPAP group, the ASV group had significantly greater reductions from baseline in AHI (-37 ± 15/h vs -28 ± 18/h, p = 0.02), arousal index (-12.7 ± 13.6/h vs -6.8 ± 12.5/h, p = 0.04) and sleep stage N1 (-9 ± 14 % vs -2 ± 12 %, p = 0.03). In addition, the ASV group gained significantly more rapid eye movement (REM) sleep compared with the CPAP group (+5 ± 9 % vs +1 ± 9 %, p = 0.02). CONCLUSIONS: CPAP therapy is effective in reducing AHI in a significant proportion of CHF patients with reduced ejection fraction and CSA. Treatment of CSA with ASV in CHF patients reduces sleep fragmentation and improves sleep structure to a significantly greater extent than changes seen in responders to CPAP therapy.
OBJECTIVES: Poor sleep quality is common in patients with chronic heart failure (CHF). This study tested the hypothesis that adaptive servo-ventilation (ASV) therapy in CHFpatients whose central sleep apnoea (CSA) was not suppressed by continuous positive airway pressure (CPAP) (CPAP-non-responders) would improve sleep quality compared to CPAP-responders receiving ongoing CPAP therapy. METHODS: Eighty-two patients with CHF (65 ± 9 years, left ventricular ejection fraction 35 ± 16 %) and CSA [apnoea-hypopnoea index (AHI) ≥15/h] were retrospectively studied. Within an average of 47 days, patients were reevaluated on CPAP therapy and stratified according to their suppression of CSA: 34 were CPAP-non-responders switched to ASV therapy the following day and 48 were CPAP-responders who continued on CPAP therapy. Polysomnographic parameters were assessed in the diagnostic night and on the last night of PAP therapy (CPAP or ASV) before the patient was discharged with the final pressure settings. RESULTS: Compared with the CPAP group, the ASV group had significantly greater reductions from baseline in AHI (-37 ± 15/h vs -28 ± 18/h, p = 0.02), arousal index (-12.7 ± 13.6/h vs -6.8 ± 12.5/h, p = 0.04) and sleep stage N1 (-9 ± 14 % vs -2 ± 12 %, p = 0.03). In addition, the ASV group gained significantly more rapid eye movement (REM) sleep compared with the CPAP group (+5 ± 9 % vs +1 ± 9 %, p = 0.02). CONCLUSIONS: CPAP therapy is effective in reducing AHI in a significant proportion of CHFpatients with reduced ejection fraction and CSA. Treatment of CSA with ASV in CHFpatients reduces sleep fragmentation and improves sleep structure to a significantly greater extent than changes seen in responders to CPAP therapy.
Authors: Andrew D Calvin; Virend K Somers; Christelle van der Walt; Christopher G Scott; Lyle J Olson Journal: Chest Date: 2011-06-02 Impact factor: 9.410
Authors: T Douglas Bradley; Alexander G Logan; R John Kimoff; Frédéric Sériès; Debra Morrison; Kathleen Ferguson; Israel Belenkie; Michael Pfeifer; John Fleetham; Patrick Hanly; Mark Smilovitch; George Tomlinson; John S Floras Journal: N Engl J Med Date: 2005-11-10 Impact factor: 91.245
Authors: Maximilian V Malfertheiner; C Lerzer; L Kolb; K Heider; F Zeman; F Gfüllner; L S Maier; M Pfeifer; M Arzt Journal: Clin Res Cardiol Date: 2017-04-17 Impact factor: 5.460
Authors: Katharina Heider; Michael Arzt; Christoph Lerzer; Leonie Kolb; Michael Pfeifer; Lars S Maier; Florian Gfüllner; Maximilian Valentin Malfertheiner Journal: Clin Res Cardiol Date: 2018-01-25 Impact factor: 5.460
Authors: Leonie Kolb; Michael Arzt; Stefan Stadler; Katharina Heider; Lars S Maier; Maximilian Malfertheiner Journal: Sleep Breath Date: 2020-09-03 Impact factor: 2.816